Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, is now the antimicrobial with greatest in vitro activity against MDR-GNB.
Original languageEnglish
Pages (from-to)102-102
Number of pages1
JournalTrials
Volume16
DOIs
Publication statusPublished - 2015

Keywords

  • Anti-Bacterial Agents
  • Clinical Protocols
  • Colistin
  • Drug Resistance, Multiple, Bacterial
  • Europe
  • Gram-Negative Bacterial Infections
  • Humans
  • Incidence
  • Patents as Topic
  • Pneumonia, Ventilator-Associated
  • Research Design
  • Thienamycins
  • Time Factors
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial'. Together they form a unique fingerprint.

Cite this